Pharma dodges Trump tariffs in first round but 3 scenarios are likely to haunt future prospects

India's pharmaceutical sector avoids immediate impact from newly declared tariffs on over 60 countries. However, HDFC Securities estimates potential hits to EBITDA ranging from 3-45% under different scenarios. Sun Pharma, Aurobindo, and Dr. Reddy’s have significant US sales, making them more vulnerable.